EGFR and non-small cell lung carcinoma: FGFR1 has previously been associated with erlotinib resistance in NSCLC15,17 and combined FGFRi and EGFR-TKI has been shown to be therapeutically beneficial in EGFR-TKI-resistant NSCLC models12,23,25.